USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
EIGER GROUP INTERNATIONAL, INC.
Address:
2061 WEBSTER ST
PALO ALTO, CA
Phone:
N/A
URL:
N/A
EIN:
126140677
DUNS:
808460070
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
STTR Phase I $600,000.00 1
STTR Phase II $3,000,000.00 1

Award List:

Advancing clemizole for hepatitis C: towards a pre-IND package

Award Year / Program / Phase:
2010 / STTR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Jeffrey S. Glenn – 650-725-3373
Research Institution:
Stanford University
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Over 150 million people worldwide are infected with the hepatitis C virus (HCV), which is an important cause of chronic liver disease. Current therapies are inadequate. Our long-term objective is to bring a new class ofanti-HCV drugs to the clinic. We recently… More

Advancing clemizole for hepatitis C: towards a pre-IND package--Phase II

Award Year / Program / Phase:
2011 / STTR / Phase II
Award Amount:
$3,000,000.00
Agency:
HHS
Principal Investigator:
Brian S. Murphy – (650) 521-0682
Research Institution:
STANFORD UNIVERSITY
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is an important worldwide cause of liver disease. Current standard of care (SOC) agents are inadequate for most patients, and new virus-specific drugs are urgently needed. Our long-term objective is to bring a new class of anti-HCV drugs… More